Bispecific Antibody Therapeutics Contract Manufacturing Market Revenue to Attain USD 218.92 Bn by 2035

Published: 28 Jan 2026

Author: Precedence Research

Share:

Bispecific Antibody Therapeutics Contract Manufacturing Market Revenue and Trends 2026 to 2035

The global bispecific antibody therapeutics contract manufacturing market revenue was valued at USD 9.82 billion in 2025 and is expected to attain around USD 218.92 billion by 2035, growing at a CAGR of 36.4% during forecast period. This market is experiencing unprecedented growth, driven by the growing demand for targeted therapies and rapid advancements in biomanufacturing technologies.

What are the Factors Boosting the Growth of the Bispecific Antibody Therapeutics Contract Manufacturing Market?

The rapid growth of biopharmaceutical outsourcing and the rising incidence of chronic diseases are the major drivers contributing to the overall growth of the bispecific antibody therapeutics contract manufacturing market. Biopharmaceutical companies are increasingly outsourcing the manufacturing of complex bispecific antibodies (bsAbs) to Contract Development and Manufacturing Organizations (CDMOs), which accelerate time-to-market and manage production costs. The market’s growth is also primarily supported by the increasing clinical trials for antibody therapeutics, expanding research and development activities for the discovery of novel therapeutics, and an increasing pipeline of anti-cancer therapeutics. Such factors are expected to fuel the market expansion in the coming years.

Segment Insights

• By molecule type/bispecific format, the full-length IgG-like bispecifics segment held the largest market share of nearly 60% in 2025, owing to the robust structural stability and long half-life. These bispecific antibodies offer superior therapeutic efficacy, particularly in the fields of oncology, infectious diseases, and autoimmune diseases.
• By expression system/host cell line, the mammalian cell systems segment dominated the market in 2024. The mammalian cell system enables the production of complex, correctly folded, and fully functional proteins for bispecific antibody therapies.
• By manufacturing stage/service scope, the clinical manufacturing segment led the market while holding the largest share of approximately 45% in 2025. The growing number of regulatory approvals and commercialization of antibody therapies fuel the need for manufacturing. The increasing demand for clinical trials for bispecific antibody therapeutics has significantly increased the demand for contract manufacturing services.
• By indication/therapeutic area, the oncology segment led the market while holding the largest share of approximately 55% in 2025, owing to the rising cases of cancer and increasing demand for innovative & targeted therapies. The bispecific antibodies offer superior therapeutic efficacy in oncology by simultaneously targeting multiple antigens or pathways.
• By route of administration, the intravenous (IV) segment held the largest market share of about 65% in 2025. The intravenous administration enables high bioavailability, which makes it highly preferred for specific antibodies. The intravenous route of administration provides immediate therapeutic effect, which has made it gain immense popularity for numerous chronic diseases, particularly in oncology.
• By end-user/contracting model, the biotech companies / emerging players segment led the market while holding the largest share of approximately 50% in 2025. Biotech companies are increasingly focusing on the development of innovative therapies, such as specific antibodies and antibody drug conjugates. These companies are forming strategic partnerships with CDMOs to accelerate development and commercialization.

Regional Insights

North America dominated the global bispecific antibody therapeutics contract manufacturing market by holding the highest market share in 2025. The region holds a strong presence of biopharmaceutical companies, pharmaceutical firms, and Contract Development and Manufacturing Organizations (CDMOs). The growth of the region is characterized by the growing demand for sophisticated & customized therapeutic solutions, increasing cases of cancer and autoimmune diseases, increasing number of BsAb candidates in clinical trials, and significant R&D investment. The region has a favorable regulatory environment, which accelerated the approval of new and innovative therapies.

On the other hand, Asia Pacific is expected to grow at a significant CAGR between 2026 and 2035. The region's market growth is attributed to the growing demand for targeted therapies, the rising trend of biopharmaceutical outsourcing, a surge in R&D spending, increasing clinical trials for antibody therapeutics, and rising cases of chronic diseases.

In January 2026, Rakuten Medical, Inc. and LOTTE Biologics announced that they had signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox platform-based photoimmunotherapy. In this partnership, LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates, supporting Rakuten Medical's global clinical development and future commercialization.

Bispecific Antibody Therapeutics Contract Manufacturin Market Coverage

Recent Development

• In October 2025, Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, announced a strategic collaboration to advance the development of multispecific ADCs. The partnership aims to accelerate the translation of bispecific and trispecific ADCs from discovery into preclinical and clinical development.(Source: https://www.businesswire.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7444

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344